clinical trial · NCT02975934
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Metastatic Castration Resistant Prostate CancerRucaparibAbiraterone acetate or Enzalutamide or Docetaxel
brief summary
The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.
started
Jun 13, 2017
primary completion
Aug 25, 2022
completion
Aug 8, 2024
last updated
Jul 25, 2025
official title
TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol